- Effect of Afatinib for Lung Cancer on Papillary Thyroid Carcinoma
-
Cho SH, Lee JS, Yun HJ, Lee YS, Chang HS
- KMID: 2536500
- Int J Thyroidol.
- 2022 Nov;15(2):131-134.
- doi: 10.11106/ijt.2022.15.2.131
Papillary thyroid carcinoma is the most common type of thyroid cancer, for which surgery following preoperative staging and risk assessment is the standard treatment. Afatinib is an orally active irreversible... -
- CITED
-
- Close
- SHARE
-
- Close
- EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
-
Park S, Ku BM, Jung HA, Sun JM, Ahn JS, Lee SH, Park K, Ahn MJ
- KMID: 2507954
- Cancer Res Treat.
- 2020 Oct;52(4):1288-1290.
- doi: 10.4143/crt.2020.278
The non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutation eventually acquires resistant to either first or second-generation EGFR tyrosine kinase inhibitor (TKI). As the following option,... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea
-
Byeon S, Kim Y, Lim SW, Cho JH, Park S, Lee J, Sun JM, Choi YL, Lee SH, Ahn JS, Park K, Ahn MJ
- KMID: 2464409
- Cancer Res Treat.
- 2019 Apr;51(2):623-631.
- doi: 10.4143/crt.2018.151
PURPOSE: Epidermal growth factor receptor (EGFR) exon 20 insertion mutations account for approximately 4% of all EGFR mutations. Given the rarity of this mutation, its clinical outcomes are not fully... -
- CITED
-
- Close
- SHARE
-
- Close
- Olmutinib Induced Lichen Planus Like Eruption
-
Oh SH, Byun HJ, Oh SJ, Jun JY, Park JH, Lee JH, Lee DY, Lee JH, Yang JM
- KMID: 2457522
- Ann Dermatol.
- 2018 Aug;30(4):451-453.
- doi: 10.5021/ad.2018.30.4.451
Drug induced lichen planus like eruption is an uncommon cutaneous adverse effect of several drugs. This appears symmetric eruption of erythematous or violaceous plaques resembling lichen planus on the trunk... -
- CITED
-
- Close
- SHARE
-
- Close
- Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer
-
Lee Y, Lee KH, Lee GK, Lee SH, Lim KY, Joo J, Go YJ, Lee JS, Han JY
- KMID: 2394819
- Cancer Res Treat.
- 2017 Oct;49(4):1001-1011.
- doi: 10.4143/crt.2016.546
PURPOSE: This phase II study examined whether the addition of simvastatin to afatinib provides a clinical benefit compared with afatinib monotherapy in previously treated patients with nonadenocarcinomatous non-small cell lung... -
- CITED
-
- Close
- SHARE
-
- Close
- Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status
-
Lee Y, Han JY, Moon SH, Nam BH, Lim KY, Lee GK, Kim HT, Yun T, An HJ, Lee JS
- KMID: 2394817
- Cancer Res Treat.
- 2017 Oct;49(4):981-989.
- doi: 10.4143/crt.2016.522
PURPOSE: Concurrent chemoradiotherapy (CCRT) is the standard care for stage III non-small cell lung cancer (NSCLC) patients; however, a more effective regimen is needed to improve the outcome by better... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Characteristics and Continued Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Administration in EGFR-mutated Non-Small Cell Lung Cancer with Skeletal Metastasis
-
Hong SH, Kim YS, Lee JE, Kim IH, Kim SJ, Han D, Yoo IR, Chung YG, Kim YH, Lee KY, Kang JH
- KMID: 2344085
- Cancer Res Treat.
- 2016 Jul;48(3):1110-1119.
- doi: 10.4143/crt.2015.289
PURPOSE: The aim of this study was to analyze clinical characteristics of skeletal metastasis in epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) and treatment outcomes of... -
- CITED
-
- Close
- SHARE
-
- Close
- The Prognostic Value of the Tumor Shrinkage Rate for Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Receiving Gefitinib
-
Park DI, Kim SY, Kim JO, Jung SS, Park HS, Moon JY, Chung CU, Kim SS, Seo JH, Lee JE
- KMID: 2320699
- Tuberc Respir Dis.
- 2015 Oct;78(4):315-320.
- doi: 10.4046/trd.2015.78.4.315
BACKGROUND: The efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy can be measured based on the rate of treatment response, based on the Response Evaluation Criteria in... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Patient with Lung Adenocarcinoma with Double Rare EGFR Mutation of G719C and L861Q
-
Yun JT, Kim GJ, Kim SY, Jeong JW, Park SY, Yang YJ, Park JC
- KMID: 1967200
- Keimyung Med J.
- 2014 Dec;33(2):132-133.
- doi: 10.0000/kmj.2014.33.2.132
The vast majority of epidermal growth factor receptor (EGFR) gene mutations are detected in lung adenocarcinoma. EGFR mutations are the strongest predictor of response to EGFR tyrosine kinase inhibitor (TKI)... -
- CITED
-
- Close
- SHARE
-
- Close
- Systemic Nocardiosis Mimicking Disease Flare-up after Discontinuation of Gefitinib in a Patient with EGFR-Mutant Lung Cancer
-
Choi M, Lee Y, Hwang SH, Lee JS
- KMID: 1842996
- Tuberc Respir Dis.
- 2014 Dec;77(6):271-273.
- doi: 10.4046/trd.2014.77.6.271
Disease flare-up after discontinuing epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) has been considered as a critical issue in lung cancer patients who have experienced radiologic progression after... -
- CITED
-
- Close
- SHARE
-
- Close
- Gefitinib Inhibits the Growth of Toxoplasma gondii in HeLa Cells
-
Yang Z, Ahn HJ, Nam HW
- KMID: 1792207
- Korean J Parasitol.
- 2014 Aug;52(4):439-441.
- doi: 10.3347/kjp.2014.52.4.439
Toxoplasma gondii is the causative agent of toxoplasmosis with symptoms of congenital neurological and ocular diseases and acquired lymphadenitis, retinochoroiditis, and meningoencephalitis. Small molecules which block the activity of protein... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
-
Lee JC, Jang SH, Lee KY, Kim YC
- KMID: 2167612
- Cancer Res Treat.
- 2013 Jun;45(2):79-85.
Since the first description of non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutation as a distinct clinical entity, studies have proved EGFR tyrosine kinase inhibitors... -
- CITED
-
- Close
- SHARE
-
- Close
- Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Inhibitors and Overcoming Strategies in Lung Cancer
-
Choi CM, Lee JC
- KMID: 2199830
- J Lung Cancer.
- 2012 Dec;11(2):59-65.
- doi: 10.6058/jlc.2012.11.2.59
Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib and erlotinib show good response and survival benefit in EGFR-mutant lung cancer, acquired resistance inevitably develops which limits... -
- CITED
-
- Close
- SHARE
-
- Close
- EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR-TKI
-
Jung M, Cho BC, Lee CH, Park HS, Kang YA, Kim SK, Chang J, Kim DJ, Rha SY, Kim JH, Lee JH
- KMID: 1414254
- Yonsei Med J.
- 2012 Nov;53(6):1128-1135.
- doi: 10.3349/ymj.2012.53.6.1128
PURPOSE: Mutations in the epidermal growth factor receptor (EGFR) have been confirmed as predictors of the efficacy of treatment with EGFR-tyrosine kinase inhibitors (TKIs). We investigated whether polymorphisms of the... -
- CITED
-
- Close
- SHARE
-
- Close
